Novo Nordisk’s Next Move in Diabetes: New CagriSema Injection Devices Enter Phase 2

Novo Nordisk (NVO) announced an update on their ongoing clinical study.

Novo Nordisk Tests New CagriSema Injection Devices in Type 2 Diabetes

Study Overview: Novo Nordisk has launched a phase 2 study called “A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 Diabetes.” The goal is to see how well a new diabetes drug mix, CagriSema, lowers blood sugar when given through two different injection devices. The study focuses on ease of use, safety, and blood sugar control, which could shape how future injectable diabetes treatments are delivered in everyday care.

Intervention/Treatment: The trial tests CagriSema, a once-weekly injectable drug that combines two active components (cagrilintide and semaglutide). It is compared across two device types to find which version offers the best mix of blood sugar control, patient experience, and safety. A matching placebo is used to keep the comparison balanced and blinded.

Study Design: This is an interventional, phase 2 trial in people with type 2 diabetes. Participants are randomly assigned to one of two groups, each using a different injection device. Both patients and study staff are kept unaware of which device version is active, which reduces bias. The main aim is treatment: to see how well each device delivers CagriSema and supports blood sugar control over the study period.

Study Timeline: The study is listed as “not yet recruiting,” with the first submission and latest update recorded on 21 January 2026, signaling that set-up work is in progress. The trial is planned to run for about 38 weeks per participant, covering dose escalation and follow-up. Primary completion and final completion dates are not yet posted, which is typical for a newly registered phase 2 study and means investors should view this as an early- to mid-stage pipeline event.

Market Implications: For Novo Nordisk (NVO), this study is another step in expanding its diabetes and obesity franchise beyond existing GLP-1 products like Ozempic and Wegovy. Success with CagriSema, especially in a user-friendly device, could support stronger long-term growth and protect market share as competition from Eli Lilly and others intensifies in metabolic drugs. While this particular update is early stage and unlikely to move the stock on its own, it reinforces Novo Nordisk’s strategy to deepen its portfolio with next-generation injectables. Investors should see this as incremental positive news that supports the company’s pipeline story rather than a near-term earnings driver.

The study is currently in the start-up phase and remains ongoing or recently updated, with further details available on the ClinicalTrials portal.

To learn more about NVO’s potential, visit the Novo Nordisk drug pipeline page.